

Special Issue

Recent Research on Neutralizing Antibody Response to SARS-CoV-2 Variants

Message from the Guest Editor

COVID-19 continues to spread globally. Despite vaccination boosting, the risk of getting infected or reinfected with SARS-CoV-2 remains due to the emergence of viral variants. Often, these variants may evade naturally acquired or vaccine-induced immunity. Therefore, it is essential to study the relationship between genetic diversity, antibody response, and the evolution of SARS-CoV-2. The aim of this Special Issue is to evaluate recent research on the neutralizing antibody response to SARS-CoV-2 variants. We welcome original research articles and reviews. Research areas may include but are not limited to SARS-CoV-2 and vaccines, SARS-CoV-2 and natural infection, immunity mechanisms, competition between variants, vaccine escape, and SARS-CoV-2 dynamics. We look forward to receiving your contributions.

Guest Editor

Dr. Chloé Dimeglio

Virology Laboratory, Toulouse University Hospital, 31300 Toulouse, France

Deadline for manuscript submissions

closed (6 August 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/198626

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).